GT201400191A - Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento - Google Patents

Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento

Info

Publication number
GT201400191A
GT201400191A GT201400191A GT201400191A GT201400191A GT 201400191 A GT201400191 A GT 201400191A GT 201400191 A GT201400191 A GT 201400191A GT 201400191 A GT201400191 A GT 201400191A GT 201400191 A GT201400191 A GT 201400191A
Authority
GT
Guatemala
Prior art keywords
treatment
esketamine
resistant
depression
refractory
Prior art date
Application number
GT201400191A
Other languages
English (en)
Inventor
Singh Jaskaran
Ivo Caers Lodewijk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201400191A publication Critical patent/GT201400191A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE DIRIGE A MÉTODOS PARA EL TRATAMIENTO DE DEPRESIÓN REFRACTARIA AL TRATAMIENTO O DEPRESIÓN RESISTENTE AL TRATAMIENTO QUE COMPRENDE ADMINISTRAR A UN PACIENTE QUE LO NECESITA, UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE ESKETAMINA COMO MONOTERAPIA O COMO TERAPIA DE COMBINACIÓN CON AL MENOS UN ANTIDEPRESIVO.
GT201400191A 2012-03-12 2014-09-11 Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento GT201400191A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261609641P 2012-03-12 2012-03-12
US201261610058P 2012-03-13 2012-03-13

Publications (1)

Publication Number Publication Date
GT201400191A true GT201400191A (es) 2017-07-03

Family

ID=47913632

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400191A GT201400191A (es) 2012-03-12 2014-09-11 Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento

Country Status (14)

Country Link
US (2) US20130236573A1 (es)
KR (1) KR20140136982A (es)
CN (1) CN104519878A (es)
CL (1) CL2014002406A1 (es)
CO (1) CO7071129A2 (es)
CR (1) CR20140410A (es)
GT (1) GT201400191A (es)
HK (1) HK1209323A1 (es)
MX (1) MX2014010939A (es)
NI (1) NI201400104A (es)
PE (1) PE20141906A1 (es)
PH (1) PH12014501997A1 (es)
SG (1) SG11201405530SA (es)
WO (1) WO2013138322A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US20140275278A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
AU2014250756B2 (en) 2013-04-12 2019-03-07 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
CA2936809A1 (en) * 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
EP3287124B1 (en) 2014-04-17 2022-11-30 Ketabon GmbH Oral dosage form of ketamine
WO2015171770A1 (en) * 2014-05-06 2015-11-12 Northwestern University Combinations of nmdar modulating compounds
EP3179993B1 (en) * 2014-08-13 2021-01-20 Janssen Pharmaceutica NV Esketamine for use in a method for the treatment of depression
CA2961208A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
CA2970065A1 (en) * 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20180015054A1 (en) * 2014-12-31 2018-01-18 Icahn School Of Medicine At Mount Sinai Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
WO2016172672A1 (en) * 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US20190240184A1 (en) * 2016-10-27 2019-08-08 National University Corporation Chiba University Pharmaceutical applications for (s)-norketamine and salts thereof
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
CN107823195A (zh) * 2017-11-24 2018-03-23 无锡市精神卫生中心 R‑氯胺酮在抑郁症急性期治疗中的应用
MX2020006650A (es) * 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
CA3099293A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
BR112020023882A2 (pt) * 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
WO2020027344A1 (en) * 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Ch24h inhibitors for mdd use
EP3628313B1 (en) 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP3863617A1 (en) 2018-10-11 2021-08-18 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
EP3923919A4 (en) * 2019-02-17 2022-12-07 Neurawell Therapeutics COMPOSITIONS AND METHODS FOR TREATMENT OF DEPRESSION AND OTHER DISEASES
WO2020178653A1 (en) * 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US12589083B2 (en) * 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
EP3976145B1 (en) 2019-05-31 2025-01-15 Celon Pharma S.A. An inhaler for electronically supervised parenteral administration of a pharmaceutical composition
WO2020239243A1 (en) 2019-05-31 2020-12-03 Celon Pharma S.A. Electronically supervised administration of a pharmaceutical composition
JP2022546456A (ja) * 2019-08-28 2022-11-04 ヤンセン ファーマシューティカルズ，インコーポレーテッド 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
US20220339123A1 (en) * 2019-09-13 2022-10-27 Janssen Pharmaceuticals, Inc. Intranasal administration of esketamine
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
US12268658B2 (en) 2019-12-30 2025-04-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
CN115768519A (zh) * 2020-05-28 2023-03-07 詹森药业有限公司 治疗抑郁症的方法
IL300547A (en) 2020-08-18 2023-04-01 Oakwood Laboratories LLC Microsphere formulations comprising ketamine and methods for their production and use
CN114681407A (zh) * 2020-12-30 2022-07-01 北京万全德众医药生物技术有限公司 一种盐酸艾司氯胺酮颗粒剂
JP2025087929A (ja) * 2022-02-22 2025-06-11 国立大学法人京都大学 うつ病および／またはうつ状態の治療および／または予防用医薬
WO2025057111A1 (en) * 2023-09-12 2025-03-20 Clexio Biosciences Ltd. Esketamine or a pharmaceutical salt thereof for use in a method of treating major depressive disorder
CN120919140A (zh) * 2025-09-09 2025-11-11 徐州百瑞麻醉科技研究院有限公司 一种艾司氯胺酮与米氮平协同的抗抑郁药物组合物及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176242B1 (en) * 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
EP1551393A4 (en) * 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20090306137A1 (en) * 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
RU2589692C2 (ru) * 2010-06-15 2016-07-10 Грюненталь Гмбх Фармацевтическая комбинация для лечения от боли

Also Published As

Publication number Publication date
NI201400104A (es) 2016-11-30
PH12014501997A1 (en) 2014-11-24
KR20140136982A (ko) 2014-12-01
US20130236573A1 (en) 2013-09-12
CO7071129A2 (es) 2014-09-30
SG11201405530SA (en) 2014-11-27
WO2013138322A1 (en) 2013-09-19
MX2014010939A (es) 2014-11-13
US20140093592A1 (en) 2014-04-03
CR20140410A (es) 2014-11-17
HK1209323A1 (en) 2016-04-01
CL2014002406A1 (es) 2015-01-09
PE20141906A1 (es) 2014-12-05
CN104519878A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
CR20140410A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
NI201700019A (es) Anticuerpos anti tigit
MX2015012644A (es) Tratamiento de cataplejia.
MY170713A (en) Treatment protocol of diabetes type 2
MX2019003738A (es) Compuestos antivirales.
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
LT2916860T (lt) Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
MX378108B (es) Anticuerpos anti-met y composiciones.
ES2569743R1 (es) Uso de la buprenorfina en la fabricación de un medicamento para tratar los efectos secundarios inducidos por opioides
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
EA201491581A1 (ru) Везикулярные композиции
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
EA201690938A1 (ru) Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
IN2014KN01772A (es)
BR102012013982A2 (pt) 5-fluorocitosina como um tratamento de semente
WO2014056779A8 (de) Arzneimittel zur prophylaxe und behandlung einer neurodegenerativen erkrankung
BR112015001515A2 (pt) compostos terapêuticos
EA201400970A1 (ru) Новые композиции для лечения амиотрофического бокового склероза